Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of hzVSF-v13 in Healthy Adults
NCT04817202Phase 1Completed
- Sponsor
- ImmuneMed Inc.
- Start
- Sep 2020
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of burfiralimab in coronavirus disease 2019 (COVID-19) and Chronic Hepatitis B (CHB) (12 arms), sponsored by ImmuneMed Inc. Primary endpoint: Changes from baseline QTc interval at Day 162. Started Sep 2020; status: completed.
02
Drugs
burfiralimab
03
Conditions
coronavirus disease 2019 (COVID-19)Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT04817202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04817202.